Diabetic patients taking Invokana, Farxiga, or Jardiance are on alert over reports that these SGLT2 inhibitors could possibly cause a potentially lethal flesh-eating infection of the genitals. Bloomberg recently reported that SGLT2 inhibitor-induced Fourneir’s gangrene was observed in a dozen patients between March 2013 and May 2018. All cases required surgery and in one case the condition proved fatal. The FDA has said that more ...
Diabetes Drug Linked to Flesh-Eating Genital Infection
Posted September 25, 2018 in Drug and Medical Device Lawsuits | Product News and Recalls
Known as SGLT2 inhibitors for short, sodium glucose co-transporter 2 inhibitors are a class of drugs intended for certain individuals with Type II diabetes. The drugs prevent glucose from being absorbed in the kidneys and reduce glucose in the blood by causing it to be expelled in the urine.
Unfortunately, this relatively new class of drugs has already allegedly caused enough ...
continue reading...New SGLT2 Inhibitor Joins Troubled Class of Diabetes Drugs
Posted September 16, 2015 in Drug and Medical Device Lawsuits | Product News and Recalls
According to a Nasdaq report, the U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Boehringer Ingelheim’s new type 2 diabetes drug, Synjardy. Synjardy is the latest in a new line of diabetes medications known as sodium-glucose cotransporter-2 inhibitors, called SGLT2 inhibitors for short.
SGLT2 inhibitors help lower patients’ blood sugar by preventing reabsorption of glucose in the kidneys and eliminating excess sugar through ...
continue reading...FDA: SGLT2 Inhibitors May Lead to Serious Blood Condition
Posted May 22, 2015 in Product News and Recalls
The U.S. Food and Drug Administration (FDA) has issued a Drug Safety Communication warning that the SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin may result in ketoacidosis, a serious blood condition in which the body produces excess blood acids, or ketones. Ketoacidosis may require hospitalization and in extreme cases can prove fatal. The SLGT2 inhibitors are marketed under the brand names Invokana, Invokamet, Farxiga, Jardiance, Glyxambi, and Xigduo ...
